Bioretec’s RemeOs technology marks success in U.S. orthopedic surgeries
Bioretec Ltd., a leader in biodegradable orthopedic implants, has successfully performed several cases across the United States using its innovative RemeOs technology. Surgeons have confirmed successful implantation and fracture healing in all reported cases, marking a significant milestone in the application of biodegradable materials in orthopedic surgery. This achievement underscores the effectiveness of RemeOs screws, which are designed to be absorbed and replaced by bone, thus eliminating the need for removal surgery.
The use of RemeOs technology has been met with positive feedback from surgeons, who noted the seamless integration of these implants into existing surgical techniques. The biodegradable RemeOs screws offer the added benefits of osteopromotion and bioactivity, enhancing fracture healing at the site. These attributes have made RemeOs screws a preferred choice in orthopedic procedures, providing value both in surgical outcomes and patient care.
Alan Donze, CEO of Bioretec, expressed confidence in the controlled U.S. launch of the RemeOs trauma screw. “In my short tenure with Bioretec, these excellent results and surgeon feedback have given me confidence in our plans to increase our commercialization efforts in the U.S.,” said Donze. Bioretec’s commitment to pioneering the use of biodegradable materials reflects its broader strategy to innovate within the global orthopedic trauma market, which is valued at approximately USD 7 billion.
Bioretec is advancing the development of its new RemeOs product line, which is based on a unique magnesium alloy and hybrid composite. This new generation of biodegradable materials not only enhances surgical outcomes but also aligns with Value-Based Healthcare objectives, focusing on patient value through efficient healthcare practices.
The first RemeOs product received market authorization in the U.S. in March 2023, with CE-mark approval in Europe expected by the second quarter of 2024. These regulatory milestones are pivotal for Bioretec’s strategy to expand its footprint in the international market, particularly in addressing the needs of the orthopedic sector.
The successful adoption of RemeOs technology represents a paradigm shift in orthopedic treatments, positioning Bioretec as a potential game-changer in the industry. The company’s focus on biodegradable and osteoconductive materials could significantly reduce the long-term complications associated with traditional metal implants, offering a revolutionary approach to fracture treatment and bone healing.